3rd Quarter - Report
WAXMAN STRATEGIES for BRAEBURN INC.
Firm
Client
Income
$30,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Assisting in the resolution of Drug Enforcement Administrations rules around the provision of injectable buprenorphine addressed in S 916 Protecting Patient Access to Emergency Medications Act of 2017 and HR 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEREMY SHARP | LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17 |
| HENRY WAXMAN | US House of Representatives 1975 to 2015 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.